Tirzepatide: Uses, Mechanism, and Side Effects

Managing blood sugar with diet and exercise alone is not enough for many adults and adolescents with type 2 diabetes. Tirzepatide is a prescription injectable designed to work alongside lifestyle changes to improve glycemic control.

Key takeaways

• Tirzepatide is approved under the brand name Mounjaro for type 2 diabetes in adults and in pediatric patients 10 years and older.
• It works by activating both the GIP and GLP-1 receptors, two hormone pathways involved in insulin and glucagon regulation.
• The label carries a boxed warning.
• More than 300 registered trials have studied tirzepatide, including ongoing research outside its approved indication.
• The most commonly reported issues in adverse event reports involve dosing errors and gastrointestinal symptoms, reported as counts rather than confirmed side effect rates.

What Tirzepatide Is

Tirzepatide belongs to a drug class known as GIP receptor and GLP-1 receptor agonists. It is built around a fatty diacid component that binds to albumin in the blood, which extends how long the drug remains active in the body. By activating both the GIP and GLP-1 receptors, the same receptors targeted by naturally occurring gut hormones, tirzepatide boosts insulin release after meals and lowers glucagon, the hormone that raises blood sugar. Both of these effects occur in a glucose-dependent manner, meaning the drug's action is tied to current blood sugar levels.

What Tirzepatide Is Approved For

Tirzepatide, sold as Mounjaro, is approved as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus. The label includes a boxed warning, which prescribers and patients should review with a healthcare provider.

What the Evidence Shows

Tirzepatide has been the subject of 329 registered clinical trials. Current research extends beyond its approved diabetes indication, including a Phase 4 trial examining GLP-1 agonists for physical and vascular health in postmenopausal women with obesity, and a Phase 2/3 trial investigating tirzepatide in patients treated for acute ischemic stroke following thrombectomy. Other ongoing work is examining what happens clinically and neurobehaviorally when the drug is stopped and restarted.

Reported Side Effects

Adverse event reports for tirzepatide most frequently involve dosing issues, including incorrect dose administered, extra dose administered, and off label use, each logged tens of thousands of times. Among reported symptoms, gastrointestinal effects stand out, with nausea, diarrhoea, and vomiting among the most common, alongside injection site pain. Reports of the drug being ineffective also appear. These figures reflect the number of reports submitted to a safety surveillance system, not confirmed rates of occurrence or proof that tirzepatide caused the event.